Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on July 2, 2007. The filing primarily addresses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and search fees.
- Search Firm Fee: Up to $117,000 payable to Tatum, LLC.
- Annual Base Salary: $250,000 for the new CFO.
- Maximum Annual Bonus: $100,000.
- Equity Grant: Options to acquire 225,000 shares of common stock (vesting over three years).
- Relocation/Commute Reimbursement: Up to $25,000 per year for three years, plus reimbursement for associated state and federal income taxes.
Material Changes
The material change reported is the transition of Len Stigliano from Interim Chief Financial Officer (a role held since April 9, 2007) to the permanent position of Vice President, Chief Financial Officer, and Treasurer, effective July 2, 2007.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is the Change in Control Benefits Plan, which entitles Mr. Stigliano to twelve months of severance pay if terminated in connection with a change in control of the Company.
Key Facts for Investor Verification
- Confirmation of the total cost of the executive search fee ($117,000 cap).
- Verification of the 225,000 stock option grant and its vesting schedule.
- Assessment of the long-term liability associated with the $25,000 annual commute reimbursement and tax gross-up over three years.
- Review of the Change in Control severance terms (12 months) as a potential future liability.